Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ARMP with free AI briefings, catalyst countdowns, and dilution alerts.

ARMP · Armata Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 7.7 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Dec 1, 2025, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$18.3M Cash on Hand
7.7mo Cash Runway
Follow ARMP by email Get an email when ARMP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ARMP, unsubscribe in one click. Privacy

📣 What ARMP Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
AP-PA02 Non-cystic Fibrosis Bronchiectasis Phase 2 · NCT05616221 Completed
AP-SA02 Bacteremia Phase 1/2 · NCT05184764 Completed
Antimicrobial Peptide Dental Caries Phase 2 · NCT03196219 Completed
C16G2 Gel Dental Caries Phase 2 · NCT02044081 Completed
C16G2 Rinse Dental Caries Phase 2 · NCT02044081 Completed
C16G2 Strip Dental Caries Phase 2 · NCT03052842 Completed
C16G2 Varnish Dental Caries Phase 2 · NCT03004365 Completed
AB-SA01 Healthy Volunteers Phase 1 · NCT02757755 Completed
AB-PA01 N/A · NCT03395743 No longer available

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ARMP holds $18.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.1M/quarter from operations, an estimated runway of 7.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARMP files for a raise →

👥 Who Owns ARMP

Insiders 0.6% Other 5%+ holders 99.4% Institutions (85 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Innoviva, Inc. 5%+ holder (13D) 55,467,459 149.18% 2026-05-12
Deborah Birx
Chief Executive Officer, Director · +901,226 options
Insider 198,417 0.53% 2026-07-10
Richard Rychlik
Corporate Controller and PFO · +40,000 options
Insider 10,000 0.03% 2024-03-14
Pierre Kyme
Chief Business Officer · +283,142 options
Insider 9,461 0.03% 2026-03-14

Share count 37,181,979 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ARMP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARMP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.